News

Exciting Developments in (Z)-Endoxifen Research at SABCS 2025

Exciting Developments in (Z)-Endoxifen Research at SABCS 2025

Atossa Therapeutics' Bold Moves in Breast Cancer Treatment

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is making waves in the oncology sector, focusing on innovative therapies for breast cancer. The company has recently announced that four abstracts on (Z)-endoxifen have been accepted for presentation at the renowned San Antonio Breast Cancer Symposium (SABCS), scheduled for December 2025.

Significance of (Z)-Endoxifen in Cancer Treatment

(Z)-Endoxifen is gaining recognition for its potential in transforming breast cancer treatment paradigms. Research indicates that this compound could play a vital role in not just treatment, but also in the prevention of breast cancer. As Dr. Steven Quay, President and CEO of Atossa, points out, the company is dedicated to increasing the body of clinical evidence surrounding this promising compound.

Presentation Highlights and Topics

Details of the Presentations

Attendees at SABCS 2025 can look forward to compelling poster presentations that outline the findings from studies assessing (Z)-endoxifen's efficacy. The presentations will showcase research that includes:

  • Initial results from RECAST DCIS: This multicenter platform trial evaluates active surveillance along with novel endocrine therapy agents for managing Ductal Carcinoma In Situ (DCIS).
  • Low dose (Z)-endoxifen: Findings from the I-SPY2 Endocrine Optimization Pilot will also be revealed.
  • ER? Antagonist Function: Exploring how (Z)-endoxifen maintains activity against specific mutants through various mechanisms.
  • Neoadjuvant Treatment Approaches: A randomized Phase 2 trial comparing (Z)-endoxifen in combination with Goserelin versus traditional therapies for premenopausal women with ER+/HER2- breast cancer.

Anticipation for SABCS 2025

The anticipation for SABCS 2025 is palpable within the oncology community. With a commitment to rigorous clinical evidence, Atossa Therapeutics is set to shine a spotlight on important findings that could influence future treatment strategies. By presenting these innovative studies, the company hopes to engage with healthcare professionals and stakeholders dedicated to advancing breast cancer care.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a forward-thinking clinical-stage biopharmaceutical firm focused on addressing significant unmet needs in the breast cancer landscape. Through strategic resource allocation and an emphasis on impactful data, Atossa aims to facilitate future regulatory submissions and ultimately bring its therapies to market.

Frequently Asked Questions

What is (Z)-endoxifen?

(Z)-Endoxifen is a metabolic derivative of tamoxifen that shows promise in breast cancer treatment and prevention.

Where will the SABCS 2025 take place?

The San Antonio Breast Cancer Symposium is scheduled to happen in San Antonio, Texas.

Who is presenting the abstracts at SABCS?

Dr. Steven Quay, the President and CEO of Atossa Therapeutics, will represent the company during the presentations at SABCS.

What are the key topics of discussion regarding (Z)-endoxifen?

Key topics include its role in treating DCIS, its effectiveness as a low-dose therapy, and its function against ESR1 mutants.

How can I find more information about Atossa Therapeutics?

More details about Atossa Therapeutics can be found on their official website and in their filings with the U.S. Securities and Exchange Commission.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Switchgear Monitoring Market Surges to $3.80 Billion

Updated Category News Views 31

Switchgear Monitoring: A Crucial Component in Modern Power Grids When the chips are down, it's the grid that keeps the lights on. Now, looks like switchgear monitoring systems are riding high on this global necessity. Fueled by infrastructure upgrades, the market's slated to leap from $2.36 billion in 2026 to a whopping $3.80 billion by 2031, clocking a solid 10.1% CAGR....

Continue Reading
Alfa Laval's Earnings Rise Despite Soft Q4 Outlook

Updated Category News Views 61

Understanding Alfa Laval's Third Quarter Surge Alfa Laval's third quarter report isn't just another financial document; it's a reflection of the volatility and unpredictable nature of the engineering sector. Sure, revenues and earnings have shot up, but there's a hint of caution as we steer into the fourth quarter. Order intake—a term that gives every investor a reason...

Continue Reading
Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Updated Category News Views 218

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Continue Reading
Tifosi Pizza Debuts Italian Flair at Irvine's Centerview

Updated Category News Views 45

Pizza with a Punch: Irvine's Tifosi Heats Up We've got another chef-driven concept cooking up in Irvine. This time, it's Tifosi Pizza + Trattoria stirring the pot at Centerview. The spot's bringing 'New, New York' style pizza, blending Big Apple boldness with Italian tradition, and tossing in a bit of California flair for good measure. "The main idea is to create...

Continue Reading
Honeywell Aerospace Faces Lawsuit After Stock Tumbles 23%

Updated Category News Views 164

Honeywell's Bumpy Ride Rattles Investors Something's brewing over at Honeywell Aerospace, Inc. (NASDAQ:HONA) and it's not your regular cup of joe. Investors, brace yourselves, because a securities fraud class action lawsuit is stacking up against them. With shares plummeting 23.16% in a whirlwind of a market day, it's kind of hard not to get a little riled up, isn't it?...

Continue Reading
Custom Concrete: Crafting the Perfect Poolside Paradise

Updated Category News Views 99

Concrete: The Unsung Hero of Your Pool's Success You know, everyone always raves about that sparkling pool, but let's be real—it's the concrete holding the whole gig together. James White from White's Pools in Loganville, GA, drops some knowledge in a recent HelloNation piece about the unsung hero of backyard oases: custom concrete. Yeah, it's not sexy, but when you're...

Continue Reading
Blue Moon Metals Gears Up for Springer Mine Revamp

Updated Category News Views 90

Getting Set for a Big Move Blue Moon Metals Inc. isn't sitting around with its thumbs in its pockets. The company has made some strides with their Springer Tungsten Mine project in Imlay, Nevada. Let's break down what these folks are up to. Refurbished Up for the Fast Track The rock mover here is the refurbishment of the Springer processing plant. You don't just snap your...

Continue Reading
Fluence Faces Legal Battle Amid Major Stock Plunge

Updated Category News Views 0

The High Stakes for Fluence Energy Investors Well, here's a plot twist, or perhaps not for those who've been keeping an eye on the renewable energy sector. Fluence Energy (NASDAQ:FLNC), a supposed heavyweight in energy storage and renewable innovations, is tangled in a legal web over securities fraud. As of now, Fluence has been slapped with a class action lawsuit...

Continue Reading
Amgen's Board Gains Restaurateur Gibbs Amid Strategic Shift

Updated Category News Views 156

A Heavyweight Joiner Shakes Up Amgen's Ranks You can almost feel the ground shake when Amgen, a tech giant in biotech, ropes in a high-profile namesake from outside its usual league. David W. Gibbs, the former CEO of Yum! Brands, is now staking his claim at Amgen as a member of its Board of Directors. Effective immediately, Gibbs isn’t just a filler; he's diving...

Continue Reading
EQS Group's Climate Goals Get SBTi Validation

Updated Category News Views 90

EQS Group's Bold Climate Commitments The news hits like a gust of clean air — EQS Group's climate targets are now stamped with the seal of approval from the Science Based Targets initiative (SBTi). This isn't just your typical corporate green pledge: we're talking serious, validated commitments pushing for net-zero emissions by 2050. Decoding EQS Group's Impactful...

Continue Reading
ction End -->

Top 5 Most Recently Viewed Articles

AI Innovations Driving Digital Transformation in Oil & Gas

Updated Category News Views 416

AI Innovations Driving Digital Transformation in Oil & Gas The oil and gas industry is experiencing significant growth fueled by digital transformation. Investments and partnerships have become pivotal, driving a market estimated to increase by USD 56.4 billion from 2025 to 2029. This transformation is underpinned by advancements in technology, particularly artificial...

Continue Reading
Fintech's Evolution: Embracing AI and Driving Profits Forward

Updated Category News Views 241

Fintech's New Era of Growth and Innovation Recent insights reveal that the fintech industry is experiencing remarkable growth and transformative changes. This revival is highlighted in a report from knowledgeable industry analysts who indicate that this sector is on the brink of substantial disruption through innovative technologies and calculated expansion strategies,...

Continue Reading
Greystone Logistics Enhances Shareholder Value Through Buybacks

Updated Category News Views 224

Greystone Logistics Announces Stock Buybacks In a significant move to strengthen its financial foundation, Greystone Logistics, Inc. (OTCQB: GLGI), known for its innovative approach to sustainable manufacturing, has successfully completed the redemption of $5 million Preferred Stock. Additionally, the company has repurchased an impressive 620,052 shares of its common...

Continue Reading
Caribou Biosciences Investors Urged to Act Before Deadline

Updated Category News Views 179

Important Actions for Caribou Biosciences Investors In the dynamic landscape of securities litigation, investors of Caribou Biosciences, Inc. (NASDAQ: CRBU) are facing a critical deadline. With the date of lead plaintiff designation approaching, it is essential for affected individuals to understand their rights and the necessary steps they can take to protect their...

Continue Reading
Mattr Announces Appointment of Jane Skoblo to Board of Directors

Updated Category News Views 215

Mattr Welcomes Jane Skoblo as New Director Mattr Corp. (TSX: MATR) is excited to announce the addition of Jane Skoblo to its Board of Directors. This move is part of a strategic transitional plan as the company prepares for upcoming changes in leadership. Skoblo, who officially stepped into her role on August 13, 2025, will take an active part in the Audit and...

Continue Reading